Mupirocin Infectopharm Arzneimittel Und Consilium (Mupirocin)

Mupirocin is a topical antibacterial used to manage skin and nasal infections caused by susceptible bacteria.

• Nasal carriage of Staphylococcus aureus: reduces colonisation and lowers risk of subsequent infection.
• Impetigo (superficial skin infection): clears bacterial lesions and promotes healing.
• Secondary bacterial skin infections: eradicates susceptible pathogens and assists in resolution of infected wounds.

• Mupirocin binds selectively to bacterial isoleucyl‑tRNA synthetase, preventing the attachment of isoleucine to its cognate tRNA. This inhibition halts protein synthesis, leading to bacterial growth arrest and cell death. The action is bacteriostatic at low concentrations and bactericidal at higher concentrations, targeting primarily Gram‑positive organisms such as Staphylococcus and Streptococcus species.

Mupirocin may cause local and systemic adverse reactions, most of which are mild and reversible.

Common Side Effects

• Nasal irritation: burning, stinging, or itching at the application site.
• Mild erythema: redness of the nasal mucosa.
• Dryness: sensation of dryness in the nose.
• Pruritus: localized itching.
• Headache: occasional mild headache.
• Transient taste disturbance: brief alteration in taste perception.

Serious or Rare Side Effects

• Allergic contact dermatitis: severe rash, swelling, or blistering.
• Anaphylaxis: rapid onset of systemic allergic reaction, including difficulty breathing.
• Stevens‑Johnson syndrome: rare severe skin reaction with blistering.
• Erythema multiforme: target lesions on skin or mucosa.
• Systemic toxicity: rare renal impairment with extensive absorption.
• Superinfection: overgrowth of non‑susceptible organisms.

When using Mupirocin, observe the following precautions to ensure safe and effective therapy.

• Assess bacterial susceptibility: confirm that the infecting organism is likely sensitive to mupirocin.
• Allergy screening: avoid use in patients with known hypersensitivity to mupirocin or similar antibiotics.
• Duration of therapy: limit treatment to the prescribed period to reduce resistance development.
• Concurrent topical agents: avoid applying other topical antibiotics or irritants to the same site.
• Monitor for adverse reactions: discontinue and seek medical advice if signs of severe allergy appear.
• Store at room temperature: keep below 25 °C in the original packaging, protected from moisture and direct sunlight.

Mupirocin has limited systemic absorption, but certain drug combinations may affect its safety or efficacy.

Major Interactions (Avoid)

• Concurrent use with other topical antibiotics: may increase local irritation and risk of resistance.
• Use with systemic immunosuppressants: may impair wound healing and increase infection risk.

Moderate Interactions (Monitor Closely)

• Combination with topical corticosteroids: may enhance percutaneous absorption, raising systemic exposure.
• Application with silver‑containing dressings: may reduce antibacterial activity of mupirocin.
• Use alongside oral antibiotics: may diminish the need for mupirocin, requiring therapy adjustment.
• Interaction with antiseptic solutions: may affect drug stability at the application site.